The drug developed by Texas A&M and University of Texas MD Anderson Cancer Center scientists could be an effective treatment for COVID-19 and other illnesses.
There’s a new drug in development that could prevent the next global pandemic. Researchers at the Texas A&M University Health Science Center (Texas A&M Health) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.
Results from a recent phase 2 clinical trial conducted through Houston-based biotechnology company Pulmotect, Inc. showed that it may be an effective treatment for COVID-19 and other respiratory illnesses. Patients in the trial treated with inhaled PUL-042 showed improvement in cough and shortness of breath more quickly than those who received a placebo treatment. They also experienced fewer hospitalizations and intensive care admissions.
Inhaled PUL-042 stimulates the lungs’ innate immune system, protecting against a wide variety of respiratory pathogens. The scientists behind it think PUL-042 could be directed against all existing and future variants of the COVID-19 virus, as well as future pandemics. Based on the promising results from this trial and remarkable activity in pre-clinical models, PUL-042 also has potential for use in other patient populations.
“We have not found a virus PUL-042 cannot work against in the lungs, in animal studies,” said Dr. Colin Broom, CEO of Pulmotect. “As an easily administered inhaled therapy, PUL-042 could have value in reducing the impact of COVID-19 irrespective of the development of further variants. It also has potential utility for other patient populations which we plan to explore, including immunosuppressed cancer patient.”
The innate immune system is the body’s first line of defense against invading pathogens. When germs and foreign substances enter the body, the innate immune system responds quickly to fight them off. PUL-042, the first drug in its class, is composed of two small synthetic molecules and works by stimulating specific innate immune receptors in the lung lining within minutes. Protection only lasts for about three to five days, but it can be repeatedly administered once every few days.
PUL-042 was discovered by Magnus H??k, regents and distinguished professor at the Texas A&M Health Institute of Biosciences and Technology, and Dr. Burton Dickey, chair of the pulmonary department at MD Anderson Cancer Center.
“The lungs are the point of entry for many viruses and bacteria. By activating the innate immune defense of the lungs, PUL-042 can provide effective protection against a wide range of deadly pathogens,” H??k said. “We believe that if we had this therapy available in December of 2019, we could have prevented the COVID-19 pandemic and avoided the 6 million lives lost.”
The Food and Drug Administration approved Pulmotect to begin two human clinical trials of PUL-042 last year, one focused on protection and another on treatment for COVID-19. Funding support for the trials was provided by the U.S. Department of Defense.
The Latest on: PUL-042
- Aerosmith axe Vegas gig due to Steven Tyler battling mysterious illnesson December 3, 2022 at 12:53 pm
Aerosmith axed their Las Vegas gig at the last minute on Friday evening due to Steven Tyler battling a mysterious illness.
- Natural Gas Price Fundamental Daily Forecast – EIA Report Expected to Show 82 Bcf Drawon December 1, 2022 at 4:21 am
The EIA reported the first pull of the season last week, and analysts widely expect another robust withdrawal with the next EIA print.
- Whole Foods decision to pull lobster divides enviros, polson November 27, 2022 at 6:04 pm
PORTLAND, Maine (AP) — Environmental groups are once again at odds with politicians and fishermen in New England in the wake of a decision by high-end retail giant Whole Foods to stop selling Maine ...
- Whole Foods decision to pull lobster divides enviros, polson November 27, 2022 at 2:11 pm
Environmental groups are once again at odds with politicians and fishermen in New England in the wake of a decision by high-end retail giant Whole Foods to stop selling Maine lobster PORTLAND ...
- Whole Foods decision to pull lobster divides enviros, polson November 26, 2022 at 1:15 pm
PORTLAND, Maine (AP) — Environmental groups are once again at odds with politicians and fishermen in New England in the wake of a decision by high-end retail giant Whole Foods to stop selling ...
- Benefits Of Pull-Upson November 25, 2022 at 6:23 am
In addition to working multiple muscles at the same time, the pull-up is also a multi-joint movement, an exercise that causes more than one joint to move. Here are a few benefits of pull-ups.
- UA women pull away from NAUon November 25, 2022 at 12:11 am
The University of Arkansas women's basketball team defeated Northern Arizona 82-73 in its Paradise Jam opener on Thursday night in St. Thomas, U.S. Virgin Islands. Arkansas (6-0) pulled away at ...
- USMNT’s task: Pull off an upset over powerhouse Englandon November 24, 2022 at 7:23 pm
The last time the United States played England at the World Cup, The Post dubbed it the greatest tie against the British since Bunker Hill — a shocking 1-1 draw in Rustenburg, South Africa.
- Credit Suisse Warns of $1.6 Billion Loss After Clients Pull Moneyon November 23, 2022 at 3:41 am
Credit Suisse Group AG warned it would lose around $1.6 billion in the fourth quarter after customers pulled their investments and deposits over concerns about the bank’s financial health.
- ForgeRock pares declines on report that Thoma Bravo will pull, refile deal with DOJ (update)on November 22, 2022 at 6:26 pm
ForgeRock (NYSE:FORG) pared some of earlier declines, now down 1%, after a report that Thoma Bravo plans to pull and refile its merger notice with U.S. antitrust regulators. The companies are set ...
via Bing News
The Latest on: PUL-042
[google_news title=”” keyword=”PUL-042″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News